Sachin Jain
BofA Securities, Research Division
Thank you so much for joining. My pleasure to be hosting Anthony Pagano, CFO of Genmab. We have 40 minutes. I think, Anthony will make some introductory comments, and then we’ll get into questions. Anthony, with pleasure, over to you.
Anthony Pagano
Executive VP & CFO
Great. Thank you. Pleasure to be back at the conference today, Sachin. Pleasure to have a chance to catch up with you and all of the investors today.
As we sit here in September of 2025, and just reflecting on the progress in the first 8-plus months of the year, I think we’ve been off to a remarkable start. If we think about our — 2 of our late-stage programs, EPKINLY and Rina-S, we’re very excited about the emerging target product profiles that we see, the prospects moving forward, in particular, for each of these programs, we’ve seen some pretty meaningful and important and exciting data so far this year. With Rina-S, we saw some very strong, let’s call it, proof-of-concept data, both in endometrial — second-line endometrial cancer, as well as platinum-resistant ovarian cancer. And some more data sets, at least one more data set in endometrial here at ESMO moving forward.
I think what’s emerging is a highly compelling product profile along multiple dimensions, whether it’s activity across different expression levels, response rate, duration of response as well as the safety profile. I think moving forward with Rina-S, there’s a lot to be excited about, particularly as we look forward to 2026, we see clear line of sight to the first registration — potentially registrational data with the
#Genmab #GMAB #Presents #Bank #America #Global #Healthcare #Conference #Transcript